Multiomic genomic mapping with long read sequencing

使用长读长测序进行多组基因组作图

基本信息

  • 批准号:
    10546355
  • 负责人:
  • 金额:
    $ 40.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Genomic mapping of histone post-translational modifications (PTMs), chromatin-associated proteins (CAPs), and DNA methylation (DNAme) is a powerful approach for biomedical research and drug development. Current genomics assays (e.g. ChIP-seq, CUT&RUN) rely on second generation short-read sequencing (SRS), wherein short reads (<500bp) limit the ability to a) analyze concordance of epigenomic features on a single DNA molecule and b) map to repetitive regions of the genome. Third generation long-read sequencing (LRS) platforms are capable of sequencing long reads (>10kb, even >100kb) from a single molecule, and are poised to revolutionize genomics by overcoming the significant limitations of SRS. By preserving long stretches of DNA, LRS allows relationships between features on a single molecule to be used to resolve heterogeneity within mixed populations. This is highly relevant for clinical applications, as it enables analysis of signatures of specific cells within a sample without the need for single cell assays (which generate very sparse data). Further, sequencing of long reads allows mapping to challenging and repetitive regions of the genome, which were previously “unmappable” with SRS. Development of epigenetic mapping assays that use LRS provides an unprecedented opportunity to decipher the chromatin landscape of cells within mixed populations, including within previously unmappable genomic regions. However, assays to measure epigenetic elements using LRS are lacking. Here, EpiCypher is collaborating with LRS expert Dr. Winston Timp at Johns Hopkins University to develop CUTANA-LRS, a first-in-class multiomics assay platform that leverages LRS to simultaneously profile histone PTMs or CAPs and DNAme in a single assay. The innovation of CUTANA-LRS is the development of a proprietary, nondestructive approach for epigenomic mapping that leverages a novel DNA methyltransferase fusion protein to label chromatin features of interest. This approach was inspired by related immunotethering- based approaches for genomic mapping that EpiCypher is developing and commercializing (e.g. CUT&RUN). In CUTANA-LRS, DNA molecules are labeled and preserved intact for LRS, which will allow resolution of heterogeneity within / between data types, and will provide access to previously unmappable genomic regions. Together, these advances will provide a pathway to better understand mechanisms of gene regulation and transcriptional response, including in the context of human disease. In Aim 1, we will optimize CUTANA-LRS and map multiple targets, including within challenging regions, while also profiling native DNAme. In Aim 2, we will rigorously develop CUTANA-LRS by optimizing robust protocols across diverse targets, inputs, sequencing platforms, and incorporate a targeted enrichment approach. In Aim 3, we will prepare for commercial launch of CUTANA-LRS, develop automated protocols, perform external validation, and demonstrate a clinical application. This work will establish CUTANA-LRS as a revolutionary platform for mapping and deciphering the relationships between multiple types of chromatin features with access to previously “unmappable” regions.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JONATHAN MICHAEL BURG其他文献

JONATHAN MICHAEL BURG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JONATHAN MICHAEL BURG', 18)}}的其他基金

Multiomic genomic mapping with long read sequencing
使用长读长测序进行多组基因组作图
  • 批准号:
    10685064
  • 财政年份:
    2022
  • 资助金额:
    $ 40.64万
  • 项目类别:
A molecular toolbox to accelerate drug development for histone lysine methylation regulators
加速组蛋白赖氨酸甲基化调节剂药物开发的分子工具箱
  • 批准号:
    10481092
  • 财政年份:
    2022
  • 资助金额:
    $ 40.64万
  • 项目类别:
A molecular toolbox to accelerate drug development for histone lysine methylation regulators
加速组蛋白赖氨酸甲基化调节剂药物开发的分子工具箱
  • 批准号:
    10615911
  • 财政年份:
    2022
  • 资助金额:
    $ 40.64万
  • 项目类别:
Quantitative mapping of combinatorial histone modifications
组合组蛋白修饰的定量作图
  • 批准号:
    10324501
  • 财政年份:
    2019
  • 资助金额:
    $ 40.64万
  • 项目类别:

相似海外基金

Treecle - data and automation to unlock woodland creation in the UK to achieve net zero
Treecle - 数据和自动化解锁英国林地创造以实现净零排放
  • 批准号:
    10111492
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    SME Support
STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications.
STTR 第二阶段:用于药物筛选应用的片上内皮微流体装置的优化制造和基于机器学习的自动化。
  • 批准号:
    2332121
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Cooperative Agreement
Improving access to AI automation to support new digital offerings within Professional/Financial Services
改善对人工智能自动化的访问,以支持专业/金融服务中的新数字产品
  • 批准号:
    10095096
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Collaborative R&D
SBIR Phase II: Radar-based Building Automation
SBIR 第二阶段:基于雷达的楼宇自动化
  • 批准号:
    2335079
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Cooperative Agreement
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
  • 批准号:
    10087446
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Collaborative R&D
Cost-Effective, AI-driven Automation Technology for Cell Culture Monitoring: Boosting Efficiency and Sustainability in Industrial Biomanufacturing and Streamlining Supply Chains
用于细胞培养监测的经济高效、人工智能驱动的自动化技术:提高工业生物制造的效率和可持续性并简化供应链
  • 批准号:
    10104748
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Launchpad
Sustainable Remanufacturing solution with increased automation and recycled content in laser and plasma based process (RESTORE)
可持续再制造解决方案,在基于激光和等离子的工艺中提高自动化程度和回收内容(RESTORE)
  • 批准号:
    10112149
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    EU-Funded
Automation and cost reduction of the hardware and software components of a novel indoor sustainable vertical growing solution
新型室内可持续垂直种植解决方案的硬件和软件组件的自动化和成本降低
  • 批准号:
    83007861
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Innovation Loans
Artificial intelligence coupled to automation for accelerated medicine design
人工智能与自动化相结合,加速药物设计
  • 批准号:
    EP/Z533038/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Research Grant
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 40.64万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了